Company Description
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions.
The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy.
Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum.
Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis.
The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology.
Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 4, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Reid Waldman |
Contact Details
Address: 470 James Street, Suite 2 New Haven, Connecticut 06513 United States | |
| Phone | (228) 372-3376 |
| Website | veradermics.com |
Stock Details
| Ticker Symbol | MANE |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001827635 |
| CUSIP Number | 922967104 |
| ISIN Number | US9229671048 |
| Employer ID | 84-3304423 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Reid Waldman M.D. | Chief Executive Officer and Director |
| Dominic Carrano CPA | Chief Financial Officer and Treasurer |
| Dr. Timothy Durso M.D. | Chief Technical Officer |
| Michael V. Greco J.D. | General Counsel and Secretary |
| Karl Pruss | Senior Director of Manufacturing Sciences and Technology |
| Michael Murphy R.Ph. | Vice President of Project and Program Management of Business Technology and Chief of Staff |
| Mark Neumann | Chief Commercial and Strategy Officer |
| Erika Sipperly CPA | Controller |
| Dr. Michael Smolinski Ph.D. | Vice President of Development and Scientific Operations |
| Aron Shapiro | Vice President of Clinical Development and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | D | Notice of Exempt Offering of Securities |
| May 12, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | 8-K | Current Report |
| May 7, 2026 | SCHEDULE 13G | Filing |
| May 5, 2026 | SCHEDULE 13D/A | Filing |
| May 5, 2026 | SCHEDULE 13D/A | Filing |
| May 5, 2026 | SCHEDULE 13D | Filing |
| May 1, 2026 | 8-K | Current Report |
| Apr 30, 2026 | 424B4 | Prospectus |